European Wellness Join Forces with Heidelberg University Germany in Safety and Toxicity Tests for Preclinical Anti-Aging Peptides Studies
PR93117
HEIDELBERG, Germany, Nov. 17, 2021 /PRNewswire=KYODO JBN/ --
European Wellness Academy (EWA), a member of European Wellness Biomedical Group
(EWBG), recently signed its second research contract involving General In
Vitro/In Vivo Safety and Toxicity Tests for Preclinical Studies of Regenerative
Peptides with Heidelberg University.
The research contract signed is a continuation of the previous research on the
efficacy of the Group's cutting-edge biotherapeutics including precursor
(progenitor) stem cells (PSC), precursor cells (Frozen Organo Crygenics (FOC)),
Mito Organelles (MO), Nano Organo Peptides (NOP) and exosomes.
The research mandate serves to obtain further scientific knowledge on the
preclinical safety and toxicity of regenerative peptides.
The second phase of this study will be continued by in vivo safety studies and
other safety studies where tumorigenicity study will be performed on EWBG's
Mito Organelles (MO) and Nano Organo Peptides (NOP).
The collaborated study is estimated to incur 600 thousand Euros expenditure and
is funded fully by EWBG, an award-winning European biotech group and holder of
multiple patents that specialises in the knowledge and effectiveness of
European biological medicine and bio-molecular therapies.
The research partner, Heidelberg University is Germany's oldest university and
one of the strongest research universities in all of Europe. Fifty-six Nobel
Laureates share a connection with Heidelberg University or the city of
Heidelberg, ten of whom have taught there as professors.
EWBG was represented by its Group Chairman, Prof. Dr. Mike Chan who also sits
on European Society of Preventive, Regenerative and Anti-Aging Medicine (ESAAM)
Scientific Board and heads the society's Regenerative Medicine worldwide while
Heidelberg University was represented by its Commercial Managing Director,
Katrin Erk and its Head of Anatomy and Cell Biology III, Prof. Dr. Thomas
Skutella in the signing.
"We are confident that the promising early progress of both studies will
ultimately lead us towards accomplishing successful Investigational New Drug
(IND) Submission with various regulators," said Prof. Mike, who is also an
anti-aging expert with over 30 years of experience in Regenerative Medicine.
About European Wellness Biomedical Group
European Wellness Biomedical Group (EWBG) is an award-winning European group
founded by Prof. Mike Chan and Prof. Michelle Wong in early '90s in Switzerland
through the culmination of early cell therapeutic research efforts spanning
across Switzerland, Germany, Russia and Austria since the mid '80s.
Today, EWBG is most renowned for its pioneering developments in organ-specific
precursor (progenitor) stem cell therapeutics, biological and synthetic
peptides, biological regenerative medicine, immunotherapies, nutraceuticals and
cosmeceuticals.
EWBG's multinational business divisions include research and development,
bio-manufacturing, biomedical academies for continuing education and training,
anti-ageing centres and nutraceutical product distribution to licensed
practitioners and consumers across 80 countries worldwide. EWBG also owns and
operates a growing network of internationally accredited Hospital and Medical
Centers specialising in Regenerative Biomedicine and luxury Wellness Centres
globally. Currently, the Group is headquartered in Germany and Malaysia (Asia
Pacific) with research facilities vested in Germany, Switzerland, Czech
Republic, and United Kingdom.
SOURCE: European Wellness Biomedical Group
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。